ArticleFrontiers in immunology2024

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.

Ibel Carri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.